JP6115801B2 - 腺癌の検出のための蛋白質シグネチャー／マーカー - Google Patents
腺癌の検出のための蛋白質シグネチャー／マーカー Download PDFInfo
- Publication number
- JP6115801B2 JP6115801B2 JP2010500358A JP2010500358A JP6115801B2 JP 6115801 B2 JP6115801 B2 JP 6115801B2 JP 2010500358 A JP2010500358 A JP 2010500358A JP 2010500358 A JP2010500358 A JP 2010500358A JP 6115801 B2 JP6115801 B2 JP 6115801B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- proteins
- array
- binding
- binding agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 83
- 102000004169 proteins and genes Human genes 0.000 title claims description 81
- 239000003550 marker Substances 0.000 title claims description 3
- 238000001514 detection method Methods 0.000 title description 8
- 208000009956 adenocarcinoma Diseases 0.000 title description 2
- 238000000034 method Methods 0.000 claims description 71
- 238000012360 testing method Methods 0.000 claims description 45
- 210000002966 serum Anatomy 0.000 claims description 42
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 34
- 238000002493 microarray Methods 0.000 claims description 34
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 34
- 239000011230 binding agent Substances 0.000 claims description 32
- 230000027455 binding Effects 0.000 claims description 31
- 230000004083 survival effect Effects 0.000 claims description 31
- 239000012634 fragment Substances 0.000 claims description 23
- 238000004458 analytical method Methods 0.000 claims description 16
- 238000002965 ELISA Methods 0.000 claims description 12
- 238000003556 assay Methods 0.000 claims description 8
- 230000002285 radioactive effect Effects 0.000 claims description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102000004388 Interleukin-4 Human genes 0.000 claims description 6
- 108090000978 Interleukin-4 Proteins 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 108010002616 Interleukin-5 Proteins 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102000043902 Angiomotin Human genes 0.000 claims 1
- 108700020509 Angiomotin Proteins 0.000 claims 1
- 229940122601 Esterase inhibitor Drugs 0.000 claims 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 1
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 239000002329 esterase inhibitor Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 71
- 206010028980 Neoplasm Diseases 0.000 description 49
- 239000000523 sample Substances 0.000 description 43
- 201000011510 cancer Diseases 0.000 description 37
- 102000004506 Blood Proteins Human genes 0.000 description 28
- 108010017384 Blood Proteins Proteins 0.000 description 28
- 239000000090 biomarker Substances 0.000 description 24
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 22
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 22
- 208000008443 pancreatic carcinoma Diseases 0.000 description 22
- 201000002528 pancreatic cancer Diseases 0.000 description 21
- 238000012706 support-vector machine Methods 0.000 description 21
- 238000012549 training Methods 0.000 description 18
- 230000007774 longterm Effects 0.000 description 14
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 13
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 13
- 239000013068 control sample Substances 0.000 description 12
- 108010026552 Proteome Proteins 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000012491 analyte Substances 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 238000003491 array Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000003816 Interleukin-13 Human genes 0.000 description 5
- 108090000176 Interleukin-13 Proteins 0.000 description 5
- 238000010195 expression analysis Methods 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102100023688 Eotaxin Human genes 0.000 description 4
- 101710139422 Eotaxin Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000002790 cross-validation Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 238000012775 microarray technology Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 3
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000010208 microarray analysis Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000010837 poor prognosis Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 102000049772 Interleukin-16 Human genes 0.000 description 2
- 101800003050 Interleukin-16 Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000000575 proteomic method Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101710192393 Attachment protein G3P Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000002508 contact lithography Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000012336 endoscopic ultrasonography Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 1
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- JJGWLCLUQNFDIS-GTSONSFRSA-M sodium;1-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 JJGWLCLUQNFDIS-GTSONSFRSA-M 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0705876A GB0705876D0 (en) | 2007-03-27 | 2007-03-27 | Method, array and use thereof |
| GB0705876.1 | 2007-03-27 | ||
| GB0712181.7 | 2007-06-25 | ||
| GB0712181A GB0712181D0 (en) | 2007-06-25 | 2007-06-25 | Method, array and use thereof |
| PCT/GB2008/001090 WO2008117067A2 (en) | 2007-03-27 | 2008-03-25 | Protein signature/markers for the detection of adenocarcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015108468A Division JP2015187611A (ja) | 2007-03-27 | 2015-05-28 | 腺癌の検出のための蛋白質シグネチャー／マーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010522875A JP2010522875A (ja) | 2010-07-08 |
| JP2010522875A5 JP2010522875A5 (cg-RX-API-DMAC7.html) | 2011-05-12 |
| JP6115801B2 true JP6115801B2 (ja) | 2017-04-19 |
Family
ID=39493874
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010500358A Expired - Fee Related JP6115801B2 (ja) | 2007-03-27 | 2008-03-25 | 腺癌の検出のための蛋白質シグネチャー／マーカー |
| JP2015108468A Pending JP2015187611A (ja) | 2007-03-27 | 2015-05-28 | 腺癌の検出のための蛋白質シグネチャー／マーカー |
| JP2017000956A Expired - Fee Related JP6465902B2 (ja) | 2007-03-27 | 2017-01-06 | 腺癌の検出のための蛋白質シグネチャー／マーカー |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015108468A Pending JP2015187611A (ja) | 2007-03-27 | 2015-05-28 | 腺癌の検出のための蛋白質シグネチャー／マーカー |
| JP2017000956A Expired - Fee Related JP6465902B2 (ja) | 2007-03-27 | 2017-01-06 | 腺癌の検出のための蛋白質シグネチャー／マーカー |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20100105571A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2140269B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6115801B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN101680896A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2008231575A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2681899C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2140269T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2442919T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2140269T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008117067A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008231575A1 (en) | 2007-03-27 | 2008-10-02 | Immunovia Ab | Protein signature/markers for the detection of adenocarcinoma |
| GB0723179D0 (en) * | 2007-11-27 | 2008-01-02 | Immunovia Ab | Diagnostic methods and arrays for use in the same |
| US10359425B2 (en) | 2008-09-09 | 2019-07-23 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| EP2415877A3 (en) * | 2010-02-17 | 2012-02-15 | Deutsches Krebsforschungszentrum | Means and methods for diagnosing pancreatic cancer |
| GB201009798D0 (en) | 2010-06-11 | 2010-07-21 | Immunovia Ab | Method,array and use thereof |
| US20130116150A1 (en) | 2010-07-09 | 2013-05-09 | Somalogic, Inc. | Lung Cancer Biomarkers and Uses Thereof |
| KR101857462B1 (ko) * | 2010-08-13 | 2018-05-14 | 소마로직, 인크. | 췌장암 바이오마커 및 그것의 용도 |
| GB201103726D0 (en) * | 2011-03-04 | 2011-04-20 | Immunovia Ab | Method, array and use thereof |
| GB201319878D0 (en) * | 2013-11-11 | 2013-12-25 | Immunovia Ab | Method, Array and use thereof |
| KR20150129932A (ko) * | 2014-05-12 | 2015-11-23 | 연세대학교 산학협력단 | 보체인자 b 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트 |
| GB201516801D0 (en) * | 2015-09-22 | 2015-11-04 | Immunovia Ab | Method, array and use thereof |
| RU2627448C1 (ru) * | 2016-04-05 | 2017-08-08 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" | Способ иммуногистохимического выявления антигенов в препаратах органов продуктивных и непродуктивных животных длительного хранения в фиксаторах |
| GB201608192D0 (en) * | 2016-05-10 | 2016-06-22 | Immunovia Ab | Method, array and use thereof |
| GB201701572D0 (en) | 2017-01-31 | 2017-03-15 | Immunovia Ab | Methods, arrays and uses thereof |
| GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3169789D1 (en) | 1980-05-02 | 1985-05-15 | Edward P Davis | Leg aid device |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| CA1202235A (en) * | 1983-08-30 | 1986-03-25 | Paul S. Satoh | Immunoassay for complement fragments |
| US5856090A (en) | 1994-09-09 | 1999-01-05 | The Scripps Research Institute | DNA-methylase linking reaction |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| GB9704444D0 (en) * | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| US6355623B2 (en) * | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| JP2003504088A (ja) | 1999-02-19 | 2003-02-04 | ザ ユニヴァーシティー オブ アイオワ リサーチ ファンデーション | 黄斑変性に関する診断および治療 |
| EP2277542B1 (en) | 2001-06-01 | 2014-04-16 | Cornell Research Foundation Inc. | Modified antibodies to prostrate-specific membrane antigen and uses thereof |
| US20050260639A1 (en) * | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Method for diagnosing pancreatic cancer |
| JP4679149B2 (ja) | 2002-09-30 | 2011-04-27 | オンコセラピー・サイエンス株式会社 | ヒト膵癌に関連する遺伝子およびポリペプチド |
| DE60325541D1 (de) | 2002-10-31 | 2009-02-12 | Hoffmann La Roche | Verfahren/Präparat zur Erkennung von Pankreaskrebs |
| AU2003294828A1 (en) * | 2002-12-17 | 2004-07-09 | Sinogenomax Co. Ltd. Chinese National Human Genomecenter | Specific markers for pancreatic cancer |
| JP3857241B2 (ja) * | 2003-02-17 | 2006-12-13 | スパンション インク | 昇圧電源の振幅を小さくしたチャージポンプ回路 |
| JP4194080B2 (ja) * | 2003-02-19 | 2008-12-10 | 茂 森村 | 膵癌検出用マーカー |
| KR101224235B1 (ko) | 2003-04-11 | 2013-01-25 | 메디뮨 엘엘씨 | 재조합 ｉｌ９ 항체 및 그의 용도 |
| US20040248205A1 (en) * | 2003-04-16 | 2004-12-09 | Stern Lawrence J. | Major histocompatibility complex (MHC)-peptide arrays |
| WO2004099432A2 (en) | 2003-05-02 | 2004-11-18 | The Johns Hopkins University | Identification of biomarkers for detecting pancreatic cancer |
| CA2531118C (en) | 2003-07-01 | 2013-01-08 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| EP1644732B1 (en) * | 2003-07-10 | 2010-02-24 | Central Institute For Experimental Animals | Animal model for the analysis of tumor metastasis |
| US20050277137A1 (en) * | 2003-08-15 | 2005-12-15 | University Of Pittsburgh | Diagnostic multimarker serological profiling |
| DE602004022191D1 (de) * | 2003-12-24 | 2009-09-03 | Merck Serono Sa Coinsins | Cc-chemokin-bindende zeckenproteine |
| US20060106119A1 (en) * | 2004-01-12 | 2006-05-18 | Chang-Jie Guo | Novel integration for CO and H2 recovery in gas to liquid processes |
| KR101282396B1 (ko) | 2004-05-28 | 2013-07-04 | 어젠시스 인코포레이티드 | Ｐｓｃａ 단백질에 결합하는 암 진단용 항체 |
| US8383357B2 (en) | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| AU2006235276A1 (en) * | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | CACNA1E in cancer diagnosis, detection and treatment |
| EP1910557A2 (en) | 2005-04-07 | 2008-04-16 | Chiron Corporation | Cancer-related genes |
| US8632983B2 (en) | 2005-04-15 | 2014-01-21 | Van Andel Research Institute | Biomarkers for pancreatic cancer and diagnostic methods |
| CN1851455B (zh) | 2005-04-22 | 2010-11-10 | 复旦大学附属中山医院 | 一种肿瘤标志物-血清蛋白指纹图谱的检测方法 |
| ES2743543T3 (es) * | 2005-05-05 | 2020-02-19 | Univ Drexel | Diagnóstico de patología hepática a través de la evaluación del quininógeno fucosilado |
| EP1736780A1 (en) * | 2005-06-24 | 2006-12-27 | Eppendorf Array Technologies S.A. | Method and means for detecting and/or quantifying hierarchical molecular change of a cell in response to an external stimulus |
| JP2007051880A (ja) * | 2005-08-15 | 2007-03-01 | Tokyo Univ Of Science | 膵臓癌の検出方法、膵臓癌の診断キット |
| DK1974058T3 (da) | 2006-01-11 | 2014-09-01 | Genomic Health Inc | Genekspressionsmarkører til prognosticering af kolorektal cancer |
| WO2007107774A2 (en) | 2006-03-22 | 2007-09-27 | Cartela R & D Ab | Integrin alpha-10 subunit as therapeutic target and diagnostic/prognostic marker for cancer |
| DE602007010268D1 (de) | 2006-04-18 | 2010-12-16 | Perseus Proteomics Inc | Diagnostikum und therapeutikum gegen bauchspeicheldrüsenkrebs |
| US20080038301A1 (en) * | 2006-08-08 | 2008-02-14 | The Procter & Gamble Company | Personal care product comprising collapsible water-containing capsules |
| KR100819122B1 (ko) | 2006-09-30 | 2008-04-04 | 남명진 | 췌장암 진단용 키트 |
| US9353415B2 (en) * | 2006-12-19 | 2016-05-31 | Thomson Reuters (Scientific) Llc | Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom |
| CN101246176B (zh) | 2007-02-13 | 2013-06-05 | 许洋 | 鳞状细胞癌抗原阴性宫颈癌血清蛋白质检测的质谱试剂及其制备方法 |
| AU2008231575A1 (en) | 2007-03-27 | 2008-10-02 | Immunovia Ab | Protein signature/markers for the detection of adenocarcinoma |
| GB0709092D0 (en) | 2007-05-11 | 2007-06-20 | Borrebaeck Carl | Diagnosis and method of disease |
| NZ555363A (en) | 2007-05-24 | 2009-11-27 | Pacific Edge Biotechnology Ltd | Prognosis prediction for melanoma cancer |
| CA2691980C (en) | 2007-06-29 | 2022-05-10 | Correlogic Systems, Inc. | Predictive markers for ovarian cancer |
| ES2883176T3 (es) | 2007-11-08 | 2021-12-07 | Prec Biologics Inc | Anticuerpos monoclonales recombinantes y antígenos correspondientes para cánceres de colon y de páncreas |
| GB0723179D0 (en) | 2007-11-27 | 2008-01-02 | Immunovia Ab | Diagnostic methods and arrays for use in the same |
| JP2011516826A (ja) | 2008-03-07 | 2011-05-26 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 間葉系様腫瘍細胞またはこの形成を阻害する作用剤の同定のための方法 |
| GB0815846D0 (en) | 2008-09-01 | 2008-10-08 | Immunovia Ab | diagnosis, prognosis and imaging of disease |
| CN101676300B (zh) | 2008-09-16 | 2012-05-02 | 中国科学院生物物理研究所 | 一种抑制人结肠肿瘤生长的新型抗体及其在制备用于早期诊断结直肠癌、子宫内膜癌以及胰腺癌的诊断剂中的应用 |
| CN101451975B (zh) | 2008-12-29 | 2012-01-25 | 浙江大学 | 一种检测胃癌预后与分期血清蛋白质的方法 |
| WO2010102195A2 (en) | 2009-03-06 | 2010-09-10 | The Johns Hopkins University | Annexin a11 and associated genes as biomarkers for cancer |
| JP2012520469A (ja) | 2009-03-12 | 2012-09-06 | キャンサー・プリヴェンション・アンド・キュア，リミテッド | 性別に基づく疾病の識別・評価・予防及び治療を含む、肺病の識別・評価・予防及び治療の方法並びにそのキット |
| CN101880707A (zh) | 2009-05-05 | 2010-11-10 | 中国人民解放军第二军医大学 | microRNA-21在鉴别胰腺癌中的应用 |
| CN101613748A (zh) | 2009-06-09 | 2009-12-30 | 中国人民解放军第二军医大学 | 一种检测胰腺癌血清标志物的方法 |
| RU2421149C2 (ru) | 2009-07-16 | 2011-06-20 | Ольга Васильевна Кокуева | Способ дифференциальной диагностики рака поджелудочной железы и хронического панкреатита |
| SG168431A1 (en) | 2009-07-23 | 2011-02-28 | Univ Singapore | Cancer biomarker and the use thereof |
| EP2483690A1 (de) | 2009-09-29 | 2012-08-08 | Protagen AG | Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung |
| CN102279264A (zh) | 2010-06-09 | 2011-12-14 | 李彬 | 48种恶性肿瘤标志物抗体芯片的制备方法 |
| CN106011233A (zh) | 2010-08-13 | 2016-10-12 | 莫尔豪斯医学院 | 中风的生物标记 |
| US9255142B2 (en) | 2010-09-09 | 2016-02-09 | Beijing Cotimes Biotech Co., Ltd. | Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof |
| GB201103726D0 (en) | 2011-03-04 | 2011-04-20 | Immunovia Ab | Method, array and use thereof |
| CN102201038B (zh) | 2011-04-27 | 2013-06-05 | 浙江大学 | 脑瘤p53蛋白表达检测方法 |
| CN102286464B (zh) | 2011-06-30 | 2013-07-17 | 眭维国 | 尿毒症长链非编码核糖核酸差异性表达图谱模型及其构建方法 |
| WO2013052480A1 (en) | 2011-10-03 | 2013-04-11 | The Board Of Regents Of The University Of Texas System | Marker-based prognostic risk score in colon cancer |
| WO2013106844A2 (en) | 2012-01-13 | 2013-07-18 | Oncocyte Corporation | Methods and compositions for the treatment and diaginosis of pancreatic cancer |
| CA2893745A1 (en) | 2012-12-04 | 2014-06-12 | Caris Mpi, Inc. | Molecular profiling for cancer |
| TWI658049B (zh) | 2013-03-12 | 2019-05-01 | 腫瘤療法 科學股份有限公司 | Ｋｎｔｃ２胜肽及含此胜肽之疫苗 |
| US20160033511A1 (en) | 2013-03-13 | 2016-02-04 | Creatics Llc | Methods and compositions for detecting pancreatic cancer |
| CA2904973A1 (en) | 2013-03-15 | 2014-09-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ratio based biomarkers and methods of use thereof |
| JP6683986B2 (ja) | 2013-07-10 | 2020-04-22 | 国立大学法人 東京大学 | がん幹細胞分子マーカー |
| GB201319878D0 (en) | 2013-11-11 | 2013-12-25 | Immunovia Ab | Method, Array and use thereof |
| WO2015112429A1 (en) | 2014-01-23 | 2015-07-30 | Newomics Inc | Methods and systems for diagnosing diseases |
| WO2015157557A1 (en) | 2014-04-09 | 2015-10-15 | Myriad Rbm, Inc. | Methods of diagnosing pancreatic cancer and methods related thereto |
| US10451628B2 (en) | 2014-05-07 | 2019-10-22 | University Of Utah Research Foundation | Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma |
| KR20150129932A (ko) | 2014-05-12 | 2015-11-23 | 연세대학교 산학협력단 | 보체인자 b 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트 |
| GB201501930D0 (en) | 2015-02-05 | 2015-03-25 | Univ London Queen Mary | Biomarkers for pancreatic cancer |
| CN105092845A (zh) | 2015-07-10 | 2015-11-25 | 深圳市贝沃德克生物技术研究院有限公司 | 胰腺癌蛋白生物标记物、用途及其检测芯片和检测装置 |
| CN105092844A (zh) | 2015-07-10 | 2015-11-25 | 深圳市贝沃德克生物技术研究院有限公司 | 胰腺癌蛋白生物标记物的检测试剂盒及检测系统 |
| GB201516801D0 (en) | 2015-09-22 | 2015-11-04 | Immunovia Ab | Method, array and use thereof |
| GB201608192D0 (en) | 2016-05-10 | 2016-06-22 | Immunovia Ab | Method, array and use thereof |
| GB201701572D0 (en) * | 2017-01-31 | 2017-03-15 | Immunovia Ab | Methods, arrays and uses thereof |
| US12416636B2 (en) | 2018-05-31 | 2025-09-16 | University Of Florida Research Foundation, Inc. | Personalized treatment of pancreatic cancer |
| CN111171053B (zh) | 2020-01-06 | 2021-03-05 | 丽水市中心医院 | 一种化合物在制备治疗胰腺癌药物中的应用 |
| GB202010970D0 (en) * | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
-
2008
- 2008-03-25 AU AU2008231575A patent/AU2008231575A1/en not_active Abandoned
- 2008-03-25 US US12/593,448 patent/US20100105571A1/en not_active Abandoned
- 2008-03-25 EP EP08718919.7A patent/EP2140269B1/en active Active
- 2008-03-25 CN CN200880013776A patent/CN101680896A/zh active Pending
- 2008-03-25 CN CN201710115906.1A patent/CN107102142A/zh active Pending
- 2008-03-25 DK DK08718919.7T patent/DK2140269T3/da active
- 2008-03-25 EP EP20214718.7A patent/EP3851856A3/en not_active Withdrawn
- 2008-03-25 WO PCT/GB2008/001090 patent/WO2008117067A2/en not_active Ceased
- 2008-03-25 CA CA2681899A patent/CA2681899C/en active Active
- 2008-03-25 PL PL08718919T patent/PL2140269T3/pl unknown
- 2008-03-25 ES ES08718919.7T patent/ES2442919T3/es active Active
- 2008-03-25 EP EP12163644A patent/EP2490025A3/en not_active Withdrawn
- 2008-03-25 JP JP2010500358A patent/JP6115801B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-18 AU AU2014204510A patent/AU2014204510C1/en not_active Ceased
-
2015
- 2015-05-28 JP JP2015108468A patent/JP2015187611A/ja active Pending
-
2016
- 2016-10-07 AU AU2016238939A patent/AU2016238939B2/en not_active Ceased
-
2017
- 2017-01-06 JP JP2017000956A patent/JP6465902B2/ja not_active Expired - Fee Related
- 2017-05-08 US US15/589,084 patent/US20170307620A1/en not_active Abandoned
-
2019
- 2019-09-23 US US16/578,768 patent/US11525832B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2442919T3 (es) | 2014-02-14 |
| CA2681899C (en) | 2018-06-19 |
| JP6465902B2 (ja) | 2019-02-06 |
| US20170307620A1 (en) | 2017-10-26 |
| EP2140269A2 (en) | 2010-01-06 |
| AU2008231575A1 (en) | 2008-10-02 |
| WO2008117067A3 (en) | 2008-11-20 |
| JP2017067792A (ja) | 2017-04-06 |
| EP2490025A2 (en) | 2012-08-22 |
| AU2016238939B2 (en) | 2018-08-02 |
| EP2140269B1 (en) | 2013-11-20 |
| WO2008117067A2 (en) | 2008-10-02 |
| DK2140269T3 (da) | 2013-12-16 |
| AU2014204510A1 (en) | 2014-08-07 |
| CA2681899A1 (en) | 2008-10-02 |
| US20200018760A1 (en) | 2020-01-16 |
| EP2490025A3 (en) | 2012-11-28 |
| JP2015187611A (ja) | 2015-10-29 |
| US11525832B2 (en) | 2022-12-13 |
| US20100105571A1 (en) | 2010-04-29 |
| AU2014204510B2 (en) | 2016-10-27 |
| CN101680896A (zh) | 2010-03-24 |
| PL2140269T3 (pl) | 2014-07-31 |
| CN107102142A (zh) | 2017-08-29 |
| WO2008117067A9 (en) | 2008-12-31 |
| AU2016238939A1 (en) | 2016-11-03 |
| WO2008117067A8 (en) | 2009-04-16 |
| EP3851856A2 (en) | 2021-07-21 |
| EP3851856A3 (en) | 2021-11-03 |
| AU2014204510C1 (en) | 2017-01-19 |
| JP2010522875A (ja) | 2010-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6465902B2 (ja) | 腺癌の検出のための蛋白質シグネチャー／マーカー | |
| US20200088742A1 (en) | Method, array and use for determining the presence of pancreatic cancer | |
| US20100304979A1 (en) | Diagnostic Methods and Arrays for Use in the Same | |
| CN105917230A (zh) | 用于确定胰腺癌的方法、阵列和其用途 | |
| JP6104796B2 (ja) | 方法、アレイ、およびこれらの使用 | |
| CN105283763B (zh) | 用于前列腺癌的生物标志物检测中的方法和阵列 | |
| HK1142674A (en) | Protein signature/markers for the detection of adenocarcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110325 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110325 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120323 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120711 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121127 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130221 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130228 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130523 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140217 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140515 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140522 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140815 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150528 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150604 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20150904 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160426 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160701 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160729 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170113 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170309 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6115801 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |